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ABSTRACT 
Background: E-cadherin is a well known tumor suppressor and its dysregulated 
expression correlates with tumor differentiation, metastasis and survival in esophageal 
squamous cell carcinoma (ESCC). p120 catenin is an Armadillo protein normally bound to 
E-cadherin in the cadherin-catenin complex at the adherens junction. Dysregulated 
expression and mislocalization of p120ctn affect its protective function of the complex. The 
objective of the present study was to evaluate the clinical significance of E-cadherin and 
p120ctn expression in ESCC.  
Methods: Immunohistochemistry was performed to investigate the expression of 
E-cadherin and p120ctn proteins in 71 ESCC patients. The relationships between protein 
expression and clinicopathological characteristics were analyzed.  
Results: Reduced E-cadherin and p120ctn expressions were observed in 42.3% and 
8.5% of ESCC cases respectively. Reduction of membranous p120ctn was observed in 
33.8% of cases. Membranous E-cadherin was preserved when p120ctn co-localized on the 
membrane of tumor cells (72.3%, P=0.001). High level E-cadherin expression and 
membranous p120ctn preservation positively correlated with tumor differentiation 
(P=0.001 and P=0.008 respectively). p120ctn expression was also significantly related to 
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lymph node metastasis (P=0.003). Heterogeneous expression of both E-cadherin and 
p120ctn was observed in dysplasia.  
Conclusions: Altered E-cadherin expression and p120ctn localization were related to 
tumor differentiation, indicating their important roles in the pathogenesis of ESCC. 
 
Key Words: E-cadherin, esophageal squamous cell carcinoma (ESCC), 
immunohistochemistry, p120 catenin, tumor differentiation. 
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INTRODUCTION 
Esophageal cancer is the sixth most frequent cause of cancer death in the world. Among 
all histological subtypes, squamous cell carcinoma (ESCC) is the commonest one in Asia 
and locally in Hong Kong.1 Unfortunately, the overall prognosis remains relatively poor, 
mostly because of late diagnosis, the propensity of early spread of disease, and its 
occurrence in a group of elderly patients with co-morbid illnesses. The identification of a 
sensitive and representative disease marker is important for prognostication and to guide 
appropriate treatment.2 
E-cadherin is a 120kDa transmembrane glycoprotein belonging to the superfamily of 
Ca2+-dependent cell adhesion molecules. It is mainly found in epithelial cells and plays a 
key role in cell-cell interaction. Normally E-cadherin functions as a mediator for tight 
intercellular adhesion, cell polarity and tissue architecture maintenance.3 It is also a well 
known tumor suppressor and downregulation of protein expression has been reported in 
many cancers including gastric, colorectal, breast and bladder cancers.4-12 Genetic 
mutations, loss of heterozygosity and hypermethylation of its promoter are some factors 
causing dysregulated E-cadherin expression in carcinomas.13,14 In ESCC, reduced 
E-cadherin expression has been reported to correlate with tumor differentiation, metastasis 
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and prognosis.15-21 
p120 catenin (p120ctn) was first identified to be an efficient tyrosine kinase substrate 
implicated in cell transformation by Src. It belongs to the Armadillo protein superfamily 
due to the possession of 10 Arm repeats.  The human p120ctn gene (CTNND1) consists of 
21 exons and makes up to 32 isoforms resulting from alternative splicing.  Isoforms 1 to 4 
differs from each other by four different start sites and additional splicing products are 
formed by combinations of alternatively existing exons A (exon 18), B (exon 20) and C 
(exon 11).22 p120ctn is ubiquitously expressed at high levels bound to E-cadherin on the 
plasma membrane directly at the juxtamembrane domain (JMD). It regulates cadherin 
turnover at the cell surface and its dissociation promotes cadherin internalization. It also 
stabilizes E-cadherin and rescues its function post-translationally.23 Besides cellular 
adhesive function, p120ctn is also involved in the regulation of cell motility through actin 
cytoskeleton remodeling via Rho, Rac and Cdc42 GTPases.24-27 Recent studies indicated 
that p120ctn downregulation was correlated with poorly differentiated tumor and metastatic 
phenotype in certain cancers.12,28,29 
The purpose of the present study was to evaluate the clinical significance of E-cadherin 
and p120ctn expression and their inter-relationship in prognostication of ESCC. 
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MATERIALS AND METHODS 
Patients and Specimens 
Seventy-one patients with esophageal squamous cell cancers (ESCC) who underwent 
esophagectomy between 1997 and 2005 at the Department of Surgery, University of Hong 
Kong Medical Centre, Queen Mary Hospital, Hong Kong were recruited in this study. 
There were 50 men and 21 women; the mean age of the subjects was 65.0 ± 11.4 years 
(range 40 - 87 years). None of these patients had received neo-adjuvant chemotherapy or 
radiotherapy. Patient demographics and data concerning their operation, histopathology, 
and long-term follow-up data were captured in a prospectively collected database. 
Specimens of the primary tumor and non-tumor tissues from the proximal resection 
margins were obtained for storage and analyses.  
Macroscopically, the site and size of the primary tumors were recorded. Standard blocks 
were taken and fixed in 10% formalin followed by embedding in paraffin wax. Histological 
sections were cut at 4μm and stained with hematoxylin and eosin for light microscopy. 
Stained sections were reviewed and classified into different grades by the World Health 
Organization (WHO) criteria. The cancers were staged according to TNM classification.30 
Representative blocks from the tumor and non-tumor tissue from each specimen were 
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chosen for immunohistochemical study. 
Immunohistochemistry 
Both tumor and non-tumor tissue blocks were cut into 4μm-thick sections and mounted 
on glass slides. Immunohistological staining was performed using the EnVision method as 
described previously.31 Briefly, the sections were deparaffinized and rehydrated. Antigens 
were retrieved in preheated 0.2M citrate buffer (pH 6) with microwave at 95ºC for 12 
minutes. Subsequently, endogenous peroxidase activity was blocked by 3% hydrogen 
peroxide at room temperature for 20 minutes. After washing with 1x Tris buffered saline 
(TBS), nonspecific antigens were blocked with 2% bovine serum albumin (BSA, Sigma, St 
Louis, MO, USA) in TBS for 1 hour. The sections were then incubated with primary 
antibodies overnight at 4ºC. Primary antibodies included mouse monoclonal 
anti-E-cadherin (HECD-1) antibody (Cat No.13-1700, Zymed Laboratories, Carlsband, CA, 
USA) and mouse monoclonal anti-p120ctn (CT) antibody (Cat No.33-9600, Zymed 
Laboratories) in the same dilution of 1:200. Following washing with TBS, the sections 
were incubated with anti-mouse horseradish peroxidase-labeled polymer-conjugated 
secondary antibody (EnVision+ System-HRP, Cat No.K4007, DakoCytomation, Glostrup, 
Denmark) at room temperature for 30 minutes. Excess antibodies were removed by TBS 
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and signal was visualized by Liquid DAB Substrate Kit (Cat No.00-2014, Zymed 
Laboratories). Tissues were counterstained with hematoxylin and dehydrated prior to 
mounting. Negative control was designed by using mouse IgG (Cat No.02-6502, Zymed 
Laboratories) as primary antibody. Known immunoreactive sections were used as positive 
controls. 
Immunohistochemistry Evaluation 
Tissue sections were assessed by light microscopy by a pathologist (AKYL). The grading 
of immunoreactivity was conducted according to staining intensity of tumor section 
compared with that of the corresponding non-tumor tissue. Staining intensity was classified 
into two categories: (a) complete loss / reduced expression and (b) preserved staining. 
Specifically for p120ctn staining activity, localization of the protein antigen was also 
documented and was classified as (a) absent / reduced membranous staining or (b) 
preserved membranous staining. 
Statistical Analysis 
χ2 test or Fisher’s exact probability test was used to assess the association between 
immunohistochemical reactivity and clinicopathological characteristics. The Kaplan-Meier 
method was employed for survival analysis and differences in survival were estimated 
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using the log rank test. A P value less than 0.05 was considered statistically significant. All 
the statistical analyses were performed using SPSS 13.0 for Windows (Chicago, IL, USA). 
 
RESULTS 
Expression of E-cadherin and p120ctn in esophageal squamous cell carcinomas 
E-cadherin was mainly observed on the cell membrane of both non-tumor and tumor 
tissues (Fig. 1 A & C). Complete loss or reduced E-cadherin expression was detected in 
42.3% (30/71) of ESCC patients. On the other hand, p120ctn expression was well 
preserved in the majority of ESCC patients (91.5%, 65/71). Unlike E-cadherin, it was found 
on both cell membrane and cytoplasm of non-tumor cells (Fig. 1 B). Absent or reduced 
membranous p120ctn was observed in 33.8% (24/71) of ESCC patients (Fig. 1 D).   
Relationship between E-cadherin and p120ctn expression and localization 
p120ctn membranous localization was related to membranous expression of E-cadherin. 
When p120ctn was found on cell membrane, preserved membranous expression of 
E-cadherin was observed in 34 of 47 (72.3%) of patients. But when p120ctn was lost or 
accumulated in cytoplasm, membranous expression of E-cadherin was only found in 7 or 
24 (29.2%) patients (P=0.001) (Table 1). This suggests that p120ctn membrane localization 
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had direct effect on membranous expression of E-cadherin.  
Relationship between expression of E-cadherin and tumor differentiation in ESCC 
Preservation of E-cadherin was noted in all well differentiated ESCC cases (100%, 
12/12). In contrast, E-cadherin was lost or detected at low levels in most of the poorly 
differentiated ESCC patients (73.3%, 11/15).  A trend of increasing number of E-cadherin 
preserved cases from poorly to well differentiated cancer patients was observed. 
Heterogeneous expression pattern was also detected in the regions of squamous dysplasia 
(Fig. 1 E). A significant relationship was found between E-cadherin expression and ESCC 
tumor differentiation (P=0.001) (Table 2).  
Relationship between localization of p120ctn and tumor differentiation in ESCC 
Two of 12 well differentiated ESCC patients (8.3%) were found to have membranous 
loss of p120ctn from membrane to cytoplasm. The p120ctn mislocalization was detected in 
the poorly and moderately differentiated cases in 91.7%, (22/24). Among cases with 
preserved membranous p120ctn protein, 89.4% (42/47) had moderately or well 
differentiated tumors. Both gradual decrease in expression and increase in mislocalization 
of p120ctn protein were seen in squamous dysplasia (Fig. 1 F). Thus the localization of 
p120ctn significantly correlated with tumor differentiation in ESCC (P=0.008) (Table 3). 
  Chung et al 12 
Relationship between p120ctn expression and lymph node metastasis 
Among all the patients with preserved p120ctn expression, 66.2% (43/65) showed lymph 
node metastases (N1). In the cases with either complete loss or reduction in the expression 
of p120ctn, none (0%, 0/6) had lymph node metastasis (p=0.003).  
Relationship between E-cadherin and p120ctn expression and localization and 
clinicopathological features 
No statistical significant relationship was found when E-cadherin and p120ctn expression 
and localization were correlated with other clinicopathological features including age, 
gender, smoking status, level of tumor, R category, pathological T-stage and M-stage, as 
well as pathological stage (Tables 2 & 3). 
Relationship between E-cadherin and p120ctn expression and localization and 
survival 
There were no significant differences in survival when patients were grouped and 
compared according to E-cadherin expression, p120ctn expression and p120ctn localization 
(P=0.927; P=0.700 and P=0.183 respectively) (Fig. 2 A, B & C). All three factors had no 
significant predictive value in ESCC patient survival.  
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DISSCUSSION 
In the present study, we demonstrated that membranous expression of E-cadherin and 
p120ctn was found in non-tumor tissues of the esophagus, but complete loss or reduction of 
E-cadherin expression was shown in 42.3% of ESCC tumors. This is similar to other 
cancers previously reported.8,11,21,32 The reduced E-cadherin protein expression was 
associated with tumor differentiation (P=0.001) but not the other clinicopathological 
parameters that were analyzed. In previous studies, downregulated E-cadherin expression 
was also observed according to the decreasing degree of tumor differentiation in ESCC.15,16 
In esophageal adenocarcinoma, heterogeneous staining pattern with gradually diminishing 
expression of E-cadherin was seen from regions of metaplasia to dysplasia and to 
carcinoma, which indicated that the reduction of E-cadherin expression might also play a 
role in tumor progression in ESCC.33 In the present study on ESCC, heterogeneous 
expression of E-cadherin was also noted in dysplastic mucosa adjacent to the carcinoma.  
E-cadherin expression is associated with higher metastatic rate in colorectal cancer, 
ESCC and head and neck squamous cell carcinoma.8,19,34,35 However, we could not 
demonstrate any significant relationship between E-cadherin expression level and lymph 
node metastasis (P=0.332). It is worth noting that expression of N-cadherin promotes cell 
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motility, invasion and metastasis even in the presence of high level of E-cadherin in breast 
cancer.10,36 Thus, other cadherins such as N-cadherin may participate in intercellular 
adhesion compensating the loss of E-cadherin function.11 Another reason for the preserved 
level of E-cadherin in ESCC with lymph node metastasis might be the detected proteins 
were the mutant with a larger molecular weight but no cell-cell adhesion ability.37  
p120ctn normally binds to the juxtamembrane domain (JMD) of E-cadherins exerting a 
stabilizing effect in normal tissue.23 In earlier studies, p120ctn protein was detected in 
cell-cell boundaries in benign tumors and normal tissues but in cytoplasm in 
carcinomas.9,28,38 In our IHC results, it did not show an overall decreased expression of 
p120ctn in most of the ESCC cases, but absent or decreased membranous expression and 
cytoplasmic accumulation were observed. Since p120ctn is a metabolically stable protein, 
its expression and half-life are not affected by the absence of cadherins and that might be 
the reason why our findings did not show a significant relationship between E-cadherin 
expression and p120ctn expression (P=0.233) (Data not shown).39-41 
In this study, mislocalization of p120ctn from cell membrane to cytoplasm was 
significantly associated with the loss or reduction in membranous E-cadherin in ESCC 
(P=0.001). Recently, there were two proposed mechanisms to explain such a relationship. 
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First, mislocalization of p120ctn in cytoplasm leads to its incapability of interacting with 
E-cadherin, and consequently loses its protective effect, and eventually internalization and 
degradation of membranous E-cadherin.41 Membranous derangement of p120ctn might be 
due to the p120ctn-microtubule network association directly or indirectly through the 
interaction with kinesin,42 or an increased δ-catenin pool which competes with p120ctn for 
the JMD on cadherins.43 Second is the insufficient capture of cytoplasmic p120ctn to cell 
membrane by downregulated E-cadherin leading to accumulation of excess p120ctn in the 
cytoplasm.9,35 
In this study, p120ctn overall expression was preserved in all pathological N1 ESCC 
cases. This is in contrast to the findings of Bremnes et al. for lung cancer.29 It may be due to 
the fact that our samples are of a different cancer type by which it is not comparable as 
p120ctn expression is tissue and cell type specific.44 In addition, it has been suggested that 
different isoforms of p120ctn might display different functions. Aho and colleagues showed 
that certain isoforms of p120ctn did not induce branching phenotype while others did. 
Isoforms 4A and 1AB might have tumor-suppressor roles in skin cancer.45 Herein, we used 
a primary antibody which recognized all 4 isoforms of p120ctn and therefore all detected 
proteins were indistinguishable. The differential expression profiles of different isoforms 
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might account for the unexpected different results. It might also explain why there was no 
apparent significant relationship between p120ctn localization and pathological N-stage 
even though we understood that the p120ctn-uncoupled E-cadherin was vulnerable to 
endocytosis and hence losing its cell-cell adhesive ability.  
p120ctn has been reported as an independent prognostic marker in gastroesophageal 
adenocarcinoma.28 In the present study, p120ctn localization in ESCC showed a significant 
relationship with tumor differentiation (P=0.008). Membranous p120ctn protein was mostly 
preserved in well differentiated tumors but lost or reduced in poorly differentiated ones. It 
is also present occasionally in dysplastic mucosa, indicating that p120ctn localization might 
take part in tumor progression. However, no significant relationship between p120ctn 
expression and survival rate was noted in ESCC.  
In conclusion, E-cadherin expression and p120ctn localization were associated with 
ESCC tumor differentiation, and in addition, p120ctn expression was related to lymph node 
metastasis. To our knowledge, this was the first time that a significant relationship between 
E-cadherin expression and p120ctn localization was demonstrated in ESCC. In spite of the 
lack of prognostic value of E-cadherin and p120ctn in ESCC, assessment of both 
E-cadherin expression and co-localization of E-cadherin and p120ctn could hint to tumor 
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progression. The prevalence of changes in these markers may be useful for planning 
treatment strategy for ESCC in future clinical management and further studies on their roles 
in tumorigenesis are necessary. 
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LEGENDS TO FIGURES 
FIGURE 1. Expression of E-cadherin and p120ctn in ESCCs. A, strong membranous 
expression of E-cadherin in non-tumor tissue (x200); B, strong membranous expression of 
p120ctn in non-tumor tissue (x200); C, reduced expression of E-cadherin in tumor (x200); 
D, membranous loss and cytoplasmic accumulation of p120ctn in tumor (x400); E, 
heterogeneous expression of E-cadherin in dysplasia (x250); F, heterogeneous expression 
and localization of p120ctn in dysplasia (x250). 
 
FIGURE 2. Survival curves of ESCC patients with esophageal squamous cell carcinoma 
(ESCC), according to the expression of E-cadherin (A), expression of p120ctn (B) and 
localization of p120ctn (C). No significant difference was observed when the parameters 
were compared by log rank test. 
 
 
 
 
 
 
 
 
 









  Chung et al 29 
 
 
TABLE 1  
Relationship of E-cadherin expression and p120ctn localization 
p120ctn Localization  
 Absent / Reduced Membranous Preserved Membranous P value 
Complete Loss / 
Reduced 
17 
(23.9%) 
13 
(18.3%) E-cadherin 
Expression 
Preserved 
7 
(9.9%) 
34 
(47.9%) 
0.001 
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TABLE 2 
Relationship of E-cadherin expression and clinicopathological characteristics 
Characteristics Total Complete Loss / Reduced 
E-cadherin Expression  
n = 30/71 (42.3%) 
Preserved E-cadherin 
Expression  
n = 41/71 (57.7%) 
P value 
Age (Mean ± SD) n = 71 64.43 ± 10.27 65.34 ± 12.25 0.627 
Gender Male 
Female 
50 (70.4%)
21 (29.6%)
23 (76.7%) 
7 (23.3%) 
27 (65.9%) 
14 (34.1%) 
0.432 
Smoking 
Status 
Smoker 
Non-smoker 
35 (49.3%)
36 (50.7%)
14 (46.7%) 
16 (53.3%) 
21 (51.2%) 
20 (48.8%) 
0.811 
Level of 
Tumor 
Upper 
Middle 
Lower 
Double 
10 (14.1%)
41 (57.7%)
17 (23.9%)
3 (4.2%) 
5 (16.7%) 
14 (46.7%) 
10 (33.3%) 
1 (3.3%) 
5 (12.2%) 
27 (65.9%) 
7 (17.1%) 
2 (4.9%) 
0.339 
Tumor 
Differentiation 
Well 
Moderate 
Poor 
12 (16.9%)
44 (62.0%)
15 (21.1%)
0 (0.0%) 
19 (63.3%) 
11 (36.7%) 
12 (29.3%) 
25 (61.0%) 
4 (9.8%) 
0.001 
R Category R0 
R1/R2 
53 (74.6%)
18 (25.4%)
26 (86.7%) 
4 (13.3%) 
27 (65.9%) 
14 (34.1%) 
0.057 
Pathological 
T-Stage 
Early (T1/T2) 
Late (T3/T4) 
16 (22.5%)
55 (77.5%)
6 (20.0%) 
24 (80.0%) 
10 (24.4%) 
31 (75.6%) 
0.777 
Pathological 
N-Stage 
N0 
N1 
28 (39.4%)
43 (60.6%)
14 (46.7%) 
16 (53.3%) 
14 (34.1%) 
27 (65.9%) 
0.332 
Pathological 
M-Stage 
M0 
M1a 
M1b 
65 (91.5%)
2 (2.8%) 
4 (5.6%) 
29 (96.7%) 
0 (0.0%) 
1 (3.3%) 
36 (87.8%) 
2 (4.9%) 
3 (7.3%) 
0.350 
Pathological 
Stage 
Early (I/II) 
Advanced (III/IV) 
30 (42.3%)
41 (57.7%)
13 (43.3%) 
17 (56.7%) 
17 (41.5%) 
24 (58.5%) 
1.000 
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TABLE 3  
Relationship of p120ctn localization and clinicopathological characteristics 
Characteristics Total Absent / Reduced 
Membranous p120ctn 
n = 24/71 (33.8%) 
Preserved Membranous 
p120ctn  
n = 47/71 (66.2%) 
P value 
Age (Mean ± SD) n = 71 65.71 ± 11.54 64.57 ± 11.41  0.405 
Gender Male 
Female 
50 (70.4%)
21 (29.6%)
15 (62.5%) 
9 (37.5%) 
35 (74.5%) 
12 (25.5%) 
0.410 
Smoking 
Status 
Smoker 
Non-smoker 
35 (49.3%)
36 (50.7%)
8 (33.3%) 
16 (66.7%) 
27 (57.4%) 
20 (42.6%) 
0.079 
Level of 
Tumor 
Upper 
Middle 
Lower 
Double 
10 (14.1%)
41 (57.7%)
17 (23.9%)
3 (4.2%) 
5 (20.8%) 
14 (58.3%) 
3 (12.5%) 
2 (8.3%) 
5 (10.6%) 
27 (57.4%) 
14 (29.8%) 
1 (2.1%) 
0.203 
Tumor 
Differentiation 
Well 
Moderate 
Poor 
12 (16.9%)
44 (62.0%)
15 (21.1%)
2 (8.3%) 
12 (50.0%) 
10 (41.7%) 
10 (21.3%) 
32 (68.1%) 
5 (10.6%) 
0.008 
R Category R0 
R1/R2 
53 (74.6%)
18 (25.4%)
18 (75.0%) 
6 (25.0%) 
35 (74.5%) 
12 (25.5%) 
1.000 
Pathological 
T-Stage 
Early (T1/T2) 
Late (T3/T4) 
16 (22.5%)
55 (77.5%)
6 (25.0%) 
18 (75.0%) 
10 (21.3%) 
37 (78.7%) 
0.769 
Pathological 
N-Stage 
N0 
N1 
28 (39.4%)
43 (60.6%)
11 (45.8%) 
13 (54.2%) 
17 (36.2%) 
30 (63.8%) 
0.453 
Pathological 
M-Stage 
M0 
M1a 
M1b 
65 (91.5%)
2 (2.8%) 
4 (5.6%) 
24 (100.0%) 
0 (0.0%) 
0 (0.0%) 
41 (87.2%) 
2 (4.3%) 
4 (8.5%) 
0.188 
Pathological 
Stage 
Early (I/II) 
Advanced (III/IV) 
30 (42.3%)
41 (57.7%)
11 (45.8%) 
13 (54.2%) 
19 (40.4%) 
28 (59.6%) 
0.800 
 
